Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02459769 · ClinicalTrials.gov registry record · NA

Exercise Intervention for LGBT Cancer Survivors

A NA study of Neoplasms, sponsored by University of Rochester.

Completed
Registry status
NA
Development phase
140
Enrollment target
1
Study location

NCT02459769: Completed NA study of Neoplasms, sponsored by University of Rochester.

NCT02459769 is a NA study of Neoplasms that has completed, run by University of Rochester. The registered enrollment target is 140 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02459769, a NA study of Neoplasms, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
NA
Development phase
140 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test preliminary efficacy, as well as acceptability and feasibility, of a dyadic exercise intervention, the current study will randomize LGBT cancer survivors and their non-professional caregivers as dyads to either an individual or a dyadic Exercise for Cancer Patients (EXCAP) intervention. The primary outcome assessed will be psychological distress. Analyses will involve pre-post comparisons of outcomes across the study arms, testing the hypothesis that a 6 week, daily, dyadic exercise intervention will result in greater improvements in psychological distress than an individual intervention.

Primary Outcome

Self-reported psychological distress was measured with the Profile of Mood States (POMS) total score among LGBT cancer survivors. The POMS consists of 30 adjectives that subjects rate on a five-point scale with "1" = "Not at all" and "5" = "Extremely" to describe their moods over the past week. The total score can be calculated by adding the raw scores from tension, depression, anger, fatigue and confusion-focused items and then subtracting the vigour-focused items. This will give a value betwee

Conditions Studied

Interventions

  • BEHAVIORAL Exercise for Cancer Patients

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2015-08-15
Est. Completion 2021-02-22
Phase NA
University of Rochester

636 total trials

What the finished NCT02459769 record still lists

NCT02459769 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Exercise for Cancer Patients is the first listed.

NCT02459769 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02459769 about?

NCT02459769 is a clinical study titled "Exercise Intervention for LGBT Cancer Survivors". The purpose of this study is to test preliminary efficacy, as well as acceptability and feasibility, of a dyadic exercise intervention, the current study will randomize LGBT cancer survivors and their non-professional caregivers as dyads to either an individual or a dyadic Exercise for Cancer Patien...

What is the current status of trial NCT02459769?

This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2015-08-15. Estimated completion is 2021-02-22.

What conditions does trial NCT02459769 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT02459769?

The interventions under investigation include: Exercise for Cancer Patients (BEHAVIORAL).

Who is sponsoring clinical trial NCT02459769?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02459769 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02459769's enrollment target sits among peer trials

140 59th of 158 higher than 99 of 158 other Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02459769, the US trial registry maintained by the National Library of Medicine. NCT02459769 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.